South Korea-based Seegene has entered a worldwide collaboration agreement with US firm BD Life Sciences, a segment of Becton, Dickinson and Company (BD) to jointly develop multiplex real-time PCR reagents for the BD MAX System.
Under the deal, Seegene will develop and manufacture multiplex tests based on new DPO, TOCE, and MuDT technologies designed exclusively for BD’s molecular diagnostics platform.
BD will have worldwide commercialisation rights to these tests.
BD Life Sciences Molecular Diagnostics and Women’s Health vice-president Doug White said: "We are very pleased to partner with Seegene and incorporate their innovative proprietary technologies into our easy-to-use, fully automated BD MAX platform.
"With Seegene’s multiplex reagents that simultaneously detect and identify various types of pathogens in a single test, we will continue to expand the BD MAX assay portfolio."
The BD MAX System provides an efficient path to improved clinical outcomes by combining and automating real-time PCR extraction, amplification and detection into a single platform capable of running a range of assays across multiple disease states.
It also allows physicians to address a wide breadth of testing needs.
Seegene CEO Dr Jong-Yoon Chun said: "Our agreement with BD represents another meaningful milestone to Seegene’s global expansion initiatives in the molecular diagnostics market.
"BD’s commercial strength in the IVD market will help to bring Seegene’s powerful multiplex PCR chemistry technologies to more physicians and patients worldwide."
Seegene’s core enabling technologies include ACP, DPO, READ, TOCE and MuDT, and they are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility.